May 1999 – The CenterWatch Monthly : PDF
The Ups and Downs of SMO Usage
SMO usage is growing steadily. However, sponsor and CROs are primarily using SMOs to gain access to top sites.
SMOs appear to be outperforming independent sites in study initiation. But SMOs are more expensive.
A New Market in Long Term Care
The FDA's Geriatric Use Labeling Rule will require drug labeling information for patients aged 65 and over to be phase in over a six-year period. As a result, the need for clinical research among the elderly is expected to grow rapidly.
A number of progressive nursing homes with strong links to university medical centers are leading the way in clinical trials among the elderly. Several large players, including Omnicare-IBAH have now moved into this market.
Also in this issue:
- Eye On Osteoporosis